Phase 3 Clinical Trials With Primary Completion Dates in May 2022
This is a list of Phase 3 trials with primary completion dates in May 2022 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
|Symbol||Company||Primary Completion Date||Phase||NCT ID||Title|
|ARQT||Arcutis Biotherapeutics, Inc.||2022-05-01||Phase 3||NCT04973228||Trial of PDE4 Inhibition With Roflumilast for the Management of Seborrheic Dermatitis (STRATUM)|
|CNCE||Concert Pharmaceuticals, Inc.||2022-05-01||Phase 3||NCT04518995||A Phase 3 Study to Evaluate the Efficacy and Safety of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata (THRIVE-AA1)|
|GKOS||Glaukos Corporation||2022-05-01||Phase 3||NCT03868124||Clinical Study Comparing Two Models of a Travoprost Intraocular Implant|
|JAZZ||Jazz Pharmaceuticals plc||2022-05-01||Phase 3||NCT04657666||Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis|
|PTCT||PTC Therapeutics, Inc.||2022-05-01||Phase 3||NCT03179631||Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy|
|SELB||Selecta Biosciences, Inc.||2022-05-01||Phase 3||NCT04513366||A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy|
|VNDA||Vanda Pharmaceuticals Inc.||2022-05-01||Phase 3||NCT04819776||Evaluation of Efficacy and Safety of Iloperidone in the Treatment of Bipolar I Disorder|
|VTGN||VistaGen Therapeutics, Inc.||2022-05-01||Phase 3||NCT04754802||PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge|